Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $16.30 Consensus Price Target from Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has earned a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $16.30.

Several research analysts have weighed in on the stock. HC Wainwright reiterated a “neutral” rating and issued a $6.00 price objective on shares of Aardvark Therapeutics in a research note on Monday, July 20th. B. Riley Financial lowered their price target on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Morgan Stanley reaffirmed an “underweight” rating and issued a $3.00 price target (down from $7.00) on shares of Aardvark Therapeutics in a research note on Friday, May 15th. BTIG Research lowered Aardvark Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, Weiss Ratings raised Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 2nd.

Aardvark Therapeutics Price Performance

Shares of AARD opened at $7.56 on Tuesday. The business’s 50-day moving average is $5.42 and its 200-day moving average is $6.67. The company has a market capitalization of $165.41 million, a price-to-earnings ratio of -2.36 and a beta of 3.80. Aardvark Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $17.94.

Institutional Investors Weigh In On Aardvark Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Aardvark Therapeutics during the 2nd quarter valued at about $42,000. China Universal Asset Management Co. Ltd. bought a new position in Aardvark Therapeutics during the fourth quarter valued at approximately $47,000. Persistent Asset Partners Ltd bought a new position in Aardvark Therapeutics during the fourth quarter valued at approximately $56,000. New York State Common Retirement Fund acquired a new stake in Aardvark Therapeutics in the second quarter valued at approximately $99,000. Finally, MetLife Investment Management LLC bought a new stake in Aardvark Therapeutics in the fourth quarter worth approximately $102,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.